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ORIGINAL RESEARCH
Abstract: Psychiatric symptoms in Guillain-Barré syndrome (GBS) can include anxiety and
affective lability, which require treatment to improve functional outcomes. Three cases in
which modest doses of selective serotonin reuptake inhibitors (SSRIs), alone or in combination
with anticonvulsants, reduced symptoms of anxiety and affective lability during acute
rehabilitation of GBS are presented. These agents were both more effective and better tolerated
than benzodiazepines and appeared to facilitate engagement in rehabilitation therapies,
including psychotherapy. Further investigation of the pharmacotherapy of neuropsychiatric
disturbances in this population using prospective, blinded, placebo-controlled methods is
recommended.
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Introduction
Guillain-Barré syndrome (GBS) is an immune-mediated inflammatory disorder of
the peripheral nervous system that produces rapidly progressive demyelination and
axonal loss. Clinical hallmarks of this syndrome include symmetric progressive flaccid
muscle paresis, areflexia, ataxia, dysautonomia, and respiratory insufficiency in the
presence of an increased cerebrospinal fluid protein content, as well as
electromyography studies demonstrating evolving demyelination (Asbury et al 1978).
Psychiatric symptoms are common among persons with GBS and tend to develop
during the period of acute care (deJager and Sluiter 1991). These may include
emotional disturbances, feelings of hopelessness, and demoralization. Weiss et al
(2002) studied psychiatric symptom frequencies among 49 severely compromised
GBS patients during their intensive care unit (ICU) stay using a semi-structured
interview and ongoing psychiatric examination. Psychiatric symptoms in this group
included anxiety (82%), depressive symptoms (67%), brief reactive psychosis (25%),
and hopelessness (20%). Such symptoms occurred independently, in combination,
or as features of a subacute confusional state. At the conclusion of ICU care, 35% of
GBS patients continue to experience long-lasting distress, and 18% experience
continued anxiety (Weiss et al 2002).
Ventilator dependence has been associated with the development of psychiatric
symptoms in this context (Weiss et al 2002), but is neither necessary nor a sufficient
explanation for their development. Psychological reaction to an acute and disabling
illness is a likely contributor. However, the rates of psychiatric symptoms reported
by Weiss et al (2002) exceed those among patients with similarly acute and disabling
medical and neurological conditions (Eisendrath et al 1983). It is possible that the
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pathophysiologic process producing the acute peripheral
demyelination of GBS may also affect central nervous
system structures involved in the genesis of these symptoms,
but there is a lack of evidence at present to support that
hypothesis.
Regardless of etiology, these symptoms are clinically
significant, functionally disabling, and require treatment to
reduce psychiatric morbidity and improve functional
outcome in this population. Pain management, effective
communication, assistive devices, and treatment with
antidepressants may be helpful in the management of
psychiatric symptoms during recovery from GBS (Hund et
al 1993). Other studies have suggested that supportive
therapy (Hund et al 1993), cognitive behavioral therapy
(Dattilio and Castaldo 2001), and early education for patients
and their families (Dattilio 2002; Merkies et al 2002) may
be helpful; however, little is known about the role of
pharmacotherapy in the management of psychiatric
symptoms during recovery from GBS. This paper adds
another dimension of treatment, which has not previously
been reported. It presents the effects of modest doses of
selective serotonin reuptake inhibitors (SSRIs), alone or in
combination with other psychotropic agents and with
supportive psychotherapy, among three patients with
neuropsychiatric disturbances during their acute
rehabilitation following GBS.
Cases
All patients were evaluated in a community inpatient acute
rehabilitation hospital following medical hospitalization for
GBS. Primary diagnoses of GBS were confirmed using
clinical criteria described by Asbury et al (1978). Shortly
after rehabilitation admission, each patient was referred for
neuropsychiatric evaluation and management of severe
anxiety and affective lability, which was interfering with
recovery. Patients were followed by the neuropsychiatry
service throughout this hospitalization. Neurobehavioral
testing included the Folstein Mini-Mental State Examination
(Folstein et al 1975) and The Frontal Assessment Battery
(Dubois et al 2000). Additional information regarding
neuropsychiatric status was obtained through staff and the
patients’ family members. Two of the patients received low-
dose benzodiazepines during either their acute or
rehabilitation hospitalization as prescribed by their
primary treating physicians. Psychoeducation, supportive
psychotherapy, and other therapies (relaxation and
visualization) were also provided to the patients during the
course of acute rehabilitation.
Case 1
Patient 1 is a 56-year-old female diagnosed with GBS one
week after onset of rapidly progressive total body weakness.
At the time of onset of this illness she was described as
“mildly depressed”. During her acute care hospitalization,
she received treatment with intravenous IgG but did not
require mechanical ventilation. As her muscle weakness and
mobility impairments progressed, she developed severe
episodic anxiety, affective lability, and agitation. After
medical stabilization her mood was euthymic, but she
continued to experience paroxysms of anxiety, affective
lability (brief episodes of intense crying that did not reflect
her baseline mood state), and agitation. These symptoms
continued after admission to the rehabilitation hospital.
Additionally, the patient was described as increasingly
demanding of staff and family, particularly when in the midst
of an anxious or affectively labile episode. These symptoms
became sufficiently severe to interfere with her participation
in therapies and nursing care and prompted neuropsychiatric
consultation.
The patient reported short-lived episodes of anxiety,
which did not meet DSM-IV criteria for panic attacks. She
also experienced brief and involuntary episodes of crying
provoked by trivial or modestly sentimental stimuli
(described here as affective lability), despite an interepisodic
euthymic mood. During these episodes of anxiety and
affective lability she could become agitated, but she did not
demonstrate agitation otherwise. Additional symptoms
included insomnia, mildly impaired concentration, and mild
executive dysfunction. Medications on admission included
gabapentin 1800 mg daily, trazodone 100 mg at bedtime,
and acetaminophen/hydrocodone 5/500, averaging two to
three tablets daily.
The patient’s history included a self-reported “depressive
and anxiety disorder”. However, the interview and
examination did not provide evidence to support a DSM-
IV criteria-based diagnosis of any such mood or anxiety
disorder either in the past or at the time of consultation, but
were instead most consistent with dysregulation of affect
as described by Arciniegas and Topkoff (2000).
Escitalopram 10 mg daily was initiated. Within two days
of starting treatment with escitalopram, she reported
decreased anxiety. Concurrently the rehabilitation staff
reported a decrease in the number and intensity of crying
spells, improved frustration tolerance, and less agitation.
By day three of treatment with escitalopram, the staff and
patient reported a marked reduction in anxiety as well as
improvement in sleep and energy. She still demonstratedNeuropsychiatric Disease and Treatment 2005:1(2) 147
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demanding and impatient behavior at times, but to a
lesser degree. Five days after initiating treatment with
escitalopram, acetaminophen/hydrocodone was dis-
continued and gabapentin was increased to 2400 mg daily.
Following discontinuation of acetaminophen/hydrocodone,
she was noted to be more anxious – especially around issues
of pain – more fearful, and more affectively labile.
Accordingly, two days thereafter her dose of escitalopram
was increased to 20 mg daily. Two days after increasing her
escitalopram, the frequency and intensity of paroxysmal
anxiety and affective lability decreased. The patient reported
both improved hope regarding her recovery and a reduced
experience of pain. These improvements continued during
the next two weeks, by which time she reported her
paroxysms of anxiety and affective lability had ceased. Staff
and family corroborated the patient’s report. She was
discharged home on escitalopram 20 mg, gabapentin
2400 mg daily, and trazodone 100 mg at bedtime as needed.
Case 2
Patient 2 is a 64-year-old female with no previous psychiatric
history who was diagnosed with GBS two weeks after onset
of generalized weakness. During her acute course she
required ventilator support and underwent plasma exchange.
Records from the acute care hospital described the
development of “anxiety and depression” shortly after
admission. Whilst in acute care, she was started on
alprazolam 0.25 mg twice daily and sertraline 75 mg daily
for these symptoms. She was also treated with
acetaminophen/propoxyphene N-100 every four hours for
pain. Two months after onset of GBS, she was admitted for
neurorehabilitation. During the first four weeks of this
admission she continued to experience anxiety and
emotional disturbances that interfered with her participation
in rehabilitation therapies. Neuropsychiatric consultation
was requested by the team to evaluate and recommend
treatment for these symptoms.
She reported daily crying spells of a few minutes duration
that were under voluntary control and not bothersome to
her. She denied current symptoms of depression, and a DSM-
IV criteria-based interview suggested that she had not
experienced a depressive episode prior to or since the onset
of her GBS. Accordingly, her crying spells were regarded
as being consistent with mild affective lability following
GBS. She reported episodic anxiety and pain that persisted
despite current treatments. Her anxiety was most strongly
related to her fear of falling during transfers and therapies,
and also to her fear that she might not recover fully from
GBS. Although problematic, these symptoms did not meet
the DSM-IV criteria for panic disorder. She reported modest
improvement in her anxiety and affective symptoms
following initiation of sertraline, but she did not endorse
significant anxiolysis from alprazolam. However, she and
the rehabilitation team observed rebound anxiety that
temporally coincided with the predicted “off-period”
following each alprazolam administration. The patient did,
however, report modest improvement in her anxiety and
affective symptoms following initiation of sertraline.
Cognitive examination revealed mild cognitive impairment,
including problems with attention, spontaneous recall,
and orientation. Her history did not support a period of
hypoxia or other causes of her cognitive complaints. It
was suspected that her mild cognitive complaints were
attributable to her treatment with alprazolam and
acetaminophen/propoxyphene, and they were reduced.
Treatment with sertraline 75 mg daily alone was
recommended, and the patient was engaged in symptom-
targeted psychotherapy to learn more effect strategies for
managing her anxiety.
Within two days of reducing her alprazolam, the
frequency and severity of her affectively labile and anxious
episodes decreased. There was no evidence of
benzodiazepine withdrawal, and reducing alprazolam and
acetaminophen/propoxyphene effected improvements in
orientation and attention both objectively and subjectively.
Sertraline monotherapy afforded adequate control of her
anxiety and affective symptoms during the remainder of her
three-month course of inpatient rehabilitation, and she was
discharged home on 75 mg daily.
Case 3
Patient 3 is a 66-year-old female who presented to the
emergency department with generalized and progressive
weakness one month after a gastrointestinal viral illness.
She was hospitalized and required ventilatory support one
day after admission. Intravenous IgG was used with no
significant change in her condition. She had no previous
history of psychiatric diagnosis or treatment, but she and
her family described her as a “lifetime worrier”. She was
noted to be anxious and affectively labile during her acute
hospitalization. She was treated with diazepam, lorazepam,
alprazolam, temazepam, gabapentin, and buproprion at
varying doses and administration schedules as well as
citalopram up to 40 mg daily during that period. Notably,
the dose of citalopram was quickly titrated to 40 mg daily.
That dose escalation coincided temporally with worseningNeuropsychiatric Disease and Treatment 2005:1(2) 148
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of her anxiety and affective lability. She was subsequently
extubated and admitted to acute rehabilitation after an eight-
week stay in acute care. All agents except gabapentin 900 mg
daily and citalopram 40 mg daily were discontinued on
admission to rehabilitation. Neuropsychiatric consultation
was requested on day two of her rehabilitation hospital
admission to evaluate her continued and functionally
impairing episodic anxiety and affective lability, and to
recommend pharmacotherapy.
On examination, she endorsed brief and intense episodes
of fear and helplessness, anticipatory and generalized
anxiety, frequent crying spells, and impaired concentration.
These symptoms did not meet DSM-IV criteria for panic
disorder or panic attacks. Given the reported worsening of
her symptoms in response to rapid escalation of citalopram
dosing, this medication was decreased to 20 mg daily.
Treatment with alprazolam was restarted by her primary
team at 0.5 mg three times daily initially for the treatment
of her anxiety. Two days after decreasing her citalopram,
the patient, her family, and the hospital staff reported
substantial reductions in the patient’s episodic and
interepisodic anxiety symptoms as well as reduced affective
lability. Acetaminophen/hydrocodone 5/500 one to two
tablets twice daily was initiated by the primary team nine
days after admission because of exacerbation of pain related
to osteoarthritis. This was gradually tapered to one pill three
times daily as needed by time of discharge. Because of the
patient’s concern regarding impaired concentration,
alprazolam was gradually discontinued over the following
two weeks with no evidence of benzodiazepine withdrawal
syndrome. The patient reported improvement in
concentration and problem solving. Although infrequent and
mild episodic anxiety and crying spells persisted, neither
she nor the rehabilitation staff felt these symptoms interfered
with her treatment. Over the subsequent three weeks, her
anxiety abated and she experienced only two mild and brief
episodes of affective lability. She was discharged home on
citalopram 20 mg and gabapentin 600 mg daily.
Discussion
Among these patients, functionally impairing anxiety and
affective lability developed shortly after the onset of GBS.
These symptoms required pharmacologic intervention, and
their initial treatment during the acute care period using
combinations of SSRIs, gabapentin, trazodone,
benzodiazepines, and opiates met with variable response.
Treatment with the latter two classes of medication was
associated with symptoms of cognitive impairment,
prompting concern for their potentially adverse effects on
recovery. Cessation of benzodiazepines and opiates in these
patients was associated with improvements in arousal,
selective and sustained attention, working memory, recall,
and problem solving. Each of these patients demonstrated
substantial improvements in anxiety, affective lability, and
functional performance during treatment with modest doses
of SSRIs, alone or in combination with gabapentin. These
treatments afforded benefits on these symptoms sufficient
to prompt the patients, their families, and the rehabilitation
staff to request their continued use at the time of discharge
from acute rehabilitation.
The observation of improved anxiety and affective
lability, as well as the absence of significant adverse effects
(for example impaired cognition) with modest doses of
sertraline, escitalopram, and citalopram in the context of
recovery from GBS is consistent with the reported effects
of these agents on such symptoms among persons with other
neurological conditions (Arciniegas and Topkoff 2000;
Davies et al 2001). Also consistent with those reports is the
relatively rapid response of these symptoms to appropriate
dosing of these SSRIs, with substantial improvements
occurring within the first 3–7 days of such treatment. These
observations suggest that SSRIs may be useful for the
treatment of anxiety and affective lability in this context as
well. However, it is important to note that two of these three
patients also received concurrent treatment with gabapentin
(600–2400 mg daily). As such, it is possible that the
combination of modest doses of SSRIs and gabapentin was
operative in the symptom reductions observed in these
patients.
The validity and generalizability of treatment effects
described herein suffer all of the limitations inherent to an
uncontrolled, open-label, observational, retrospective review
of a small case series. Without the benefit of a placebo
control or no-treatment comparison group, it is not possible
to differentiate the apparent effects of the pharmacologic
interventions described herein from the effects of
spontaneous recovery, placebo-response, and combined
pharmacological and psychotherapeutic treatment. The
descriptive nature of this small case series leaves the
magnitude of the cognitive, emotional, behavioral, and
physical benefits provided by these medications uncertain.
The retrospective nature of this review carries the inevitable
biased towards the reporting of positive treatment outcomes.
However, these three cases represent a consecutive seriesNeuropsychiatric Disease and Treatment 2005:1(2) 149
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of patients with GBS in acute rehabilitation requiring
neuropsychiatric consultations for the evaluation and
treatment of anxiety and affective lability, and no other cases
were omitted from this series. Finally, the case series
includes only three patients; whether similar benefits during
treatment with modest doses of SSRIs, alone or in
combination with gabapentin, would be observed
consistently in a larger series of patients with these
neuropsychiatric symptoms during recovery from GBS
remains uncertain.
Nonetheless, these observations suggest that persons
with anxiety and affective lability during recovery from GBS
may benefit from judiciously applied pharmacotherapy, and
that modest doses of SSRIs, alone or in combination with
gabapentin, may be both more effective and better tolerated
than benzodiazepines, opiates, or combinations of all of
these agents. Further investigation of these hypotheses
using prospective, blinded, placebo-controlled, and
standardized assessment methods is needed to determine
optimal treatment strategies for neuropsychiatric symptoms
in this population.
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